Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Reguneal HCa** is a two-chamber, glucose-based peritoneal dialysis solution originally developed by Baxter for continuous ambulatory peritoneal dialysis in patients with chronic renal failure. It is supplied with an acidic glucose/electrolyte chamber and a bicarbonate-containing chamber that are mixed immediately before use, producing a neutral to near-neutral dialysate with 25 mmol/L bicarbonate and 10 mmol/L lactate buffer. The design reduces glucose degradation product formation during storage and sterilization while providing osmotic ultrafiltration and diffusive solute clearance through the peritoneal membrane. BLR350 was evaluated against Dianeal PD-2 in an 8-week randomized, multicenter, open-label Phase III non-inferiority study in Japan and demonstrated non-inferior peritoneal creatinine clearance and ultrafiltration, with improved correction of metabolic acidosis. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5648742/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reguneal HCa.